Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth

Fanuel Messaggio, Alisha M. Mendonsa, Jason Castellanos, Nagaraj Nagathihalli, Lee Gorden, Nipun Merchant, Michael Vansaun

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Obesity is a significant risk factor for pancreatic cancer, harboring a chronic inflammatory condition characterized by dysregulation of the adipokines, leptin and adiponectin, that in turn alter oncogenic signaling pathways. We and others have shown that leptin promotes the proliferation and an invasive potential of pancreatic cancer cells through STAT3 mediated signaling. However, the role of adiponectin on the tumorigenicity of pancreatic cancer has not been elucidated. Adiponectin represents an important negative regulator of cytokines, which acts through two receptors, ADIPOR1 and ADIPOR2, to elicit pro-apoptotic, anti-inflammatory, and anti-angiogenic responses. We show that the level and expression of both adiponectin receptors are decreased in pancreatic tumors relative to normal pancreatic tissue. In vitro stimulation with adiponectin or a small molecule adiponectin receptor agonist, AdipoRon, increases apoptosis while inhibiting pancreatic cancer cell proliferation, colony formation, and anchorage independent growth. In addition, adiponectin receptor agonism inhibits leptin mediated STAT3 activation. In vivo, treatment of mice with AdipoRon inhibits orthotopic pancreatic tumor growth. These results demonstrate that adiponectin receptor activation is a key regulator of pancreatic cancer growth and AdipoRon provides a rational agent for the development of novel therapeutic strategies for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)85378-85391
Number of pages14
JournalOncotarget
Volume8
Issue number49
DOIs
StatePublished - Oct 17 2017

Fingerprint

Adiponectin Receptors
Leptin
Pancreatic Neoplasms
Adiponectin
Growth
Neoplasms
Adipokines
Anti-Inflammatory Agents
Obesity
Cell Proliferation
Apoptosis
Cytokines

Keywords

  • Adipokine
  • Adiponectin
  • AdipoRon
  • Pancreatic adenocarcinoma
  • STAT3

ASJC Scopus subject areas

  • Oncology

Cite this

Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth. / Messaggio, Fanuel; Mendonsa, Alisha M.; Castellanos, Jason; Nagathihalli, Nagaraj; Gorden, Lee; Merchant, Nipun; Vansaun, Michael.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 85378-85391.

Research output: Contribution to journalArticle

Messaggio, Fanuel ; Mendonsa, Alisha M. ; Castellanos, Jason ; Nagathihalli, Nagaraj ; Gorden, Lee ; Merchant, Nipun ; Vansaun, Michael. / Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth. In: Oncotarget. 2017 ; Vol. 8, No. 49. pp. 85378-85391.
@article{c743eeada6664659912e8f7ee0ab14b5,
title = "Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth",
abstract = "Obesity is a significant risk factor for pancreatic cancer, harboring a chronic inflammatory condition characterized by dysregulation of the adipokines, leptin and adiponectin, that in turn alter oncogenic signaling pathways. We and others have shown that leptin promotes the proliferation and an invasive potential of pancreatic cancer cells through STAT3 mediated signaling. However, the role of adiponectin on the tumorigenicity of pancreatic cancer has not been elucidated. Adiponectin represents an important negative regulator of cytokines, which acts through two receptors, ADIPOR1 and ADIPOR2, to elicit pro-apoptotic, anti-inflammatory, and anti-angiogenic responses. We show that the level and expression of both adiponectin receptors are decreased in pancreatic tumors relative to normal pancreatic tissue. In vitro stimulation with adiponectin or a small molecule adiponectin receptor agonist, AdipoRon, increases apoptosis while inhibiting pancreatic cancer cell proliferation, colony formation, and anchorage independent growth. In addition, adiponectin receptor agonism inhibits leptin mediated STAT3 activation. In vivo, treatment of mice with AdipoRon inhibits orthotopic pancreatic tumor growth. These results demonstrate that adiponectin receptor activation is a key regulator of pancreatic cancer growth and AdipoRon provides a rational agent for the development of novel therapeutic strategies for pancreatic cancer.",
keywords = "Adipokine, Adiponectin, AdipoRon, Pancreatic adenocarcinoma, STAT3",
author = "Fanuel Messaggio and Mendonsa, {Alisha M.} and Jason Castellanos and Nagaraj Nagathihalli and Lee Gorden and Nipun Merchant and Michael Vansaun",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.19905",
language = "English (US)",
volume = "8",
pages = "85378--85391",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

TY - JOUR

T1 - Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth

AU - Messaggio, Fanuel

AU - Mendonsa, Alisha M.

AU - Castellanos, Jason

AU - Nagathihalli, Nagaraj

AU - Gorden, Lee

AU - Merchant, Nipun

AU - Vansaun, Michael

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Obesity is a significant risk factor for pancreatic cancer, harboring a chronic inflammatory condition characterized by dysregulation of the adipokines, leptin and adiponectin, that in turn alter oncogenic signaling pathways. We and others have shown that leptin promotes the proliferation and an invasive potential of pancreatic cancer cells through STAT3 mediated signaling. However, the role of adiponectin on the tumorigenicity of pancreatic cancer has not been elucidated. Adiponectin represents an important negative regulator of cytokines, which acts through two receptors, ADIPOR1 and ADIPOR2, to elicit pro-apoptotic, anti-inflammatory, and anti-angiogenic responses. We show that the level and expression of both adiponectin receptors are decreased in pancreatic tumors relative to normal pancreatic tissue. In vitro stimulation with adiponectin or a small molecule adiponectin receptor agonist, AdipoRon, increases apoptosis while inhibiting pancreatic cancer cell proliferation, colony formation, and anchorage independent growth. In addition, adiponectin receptor agonism inhibits leptin mediated STAT3 activation. In vivo, treatment of mice with AdipoRon inhibits orthotopic pancreatic tumor growth. These results demonstrate that adiponectin receptor activation is a key regulator of pancreatic cancer growth and AdipoRon provides a rational agent for the development of novel therapeutic strategies for pancreatic cancer.

AB - Obesity is a significant risk factor for pancreatic cancer, harboring a chronic inflammatory condition characterized by dysregulation of the adipokines, leptin and adiponectin, that in turn alter oncogenic signaling pathways. We and others have shown that leptin promotes the proliferation and an invasive potential of pancreatic cancer cells through STAT3 mediated signaling. However, the role of adiponectin on the tumorigenicity of pancreatic cancer has not been elucidated. Adiponectin represents an important negative regulator of cytokines, which acts through two receptors, ADIPOR1 and ADIPOR2, to elicit pro-apoptotic, anti-inflammatory, and anti-angiogenic responses. We show that the level and expression of both adiponectin receptors are decreased in pancreatic tumors relative to normal pancreatic tissue. In vitro stimulation with adiponectin or a small molecule adiponectin receptor agonist, AdipoRon, increases apoptosis while inhibiting pancreatic cancer cell proliferation, colony formation, and anchorage independent growth. In addition, adiponectin receptor agonism inhibits leptin mediated STAT3 activation. In vivo, treatment of mice with AdipoRon inhibits orthotopic pancreatic tumor growth. These results demonstrate that adiponectin receptor activation is a key regulator of pancreatic cancer growth and AdipoRon provides a rational agent for the development of novel therapeutic strategies for pancreatic cancer.

KW - Adipokine

KW - Adiponectin

KW - AdipoRon

KW - Pancreatic adenocarcinoma

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=85031497845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031497845&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19905

DO - 10.18632/oncotarget.19905

M3 - Article

AN - SCOPUS:85031497845

VL - 8

SP - 85378

EP - 85391

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -